Sinotherapeutics Inc. A (688247) - Total Liabilities
Based on the latest financial reports, Sinotherapeutics Inc. A (688247) has total liabilities worth CN¥145.56 Million CNY (≈ $21.30 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Sinotherapeutics Inc. A to evaluate the company's liquid asset resilience ratio.
Sinotherapeutics Inc. A - Total Liabilities Trend (2020–2025)
This chart illustrates how Sinotherapeutics Inc. A's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Sinotherapeutics Inc. A asset portfolio.
Sinotherapeutics Inc. A Competitors by Total Liabilities
The table below lists competitors of Sinotherapeutics Inc. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Longyan Zhuoyue New Energy Co Ltd
SHG:688196
|
China | CN¥982.88 Million |
|
FRoSTA AG
F:NLM
|
Germany | €217.82 Million |
|
Hunan Huamin Holdings Co Ltd
SHE:300345
|
China | CN¥3.03 Billion |
|
Algoma Central Corporation
TO:ALC
|
Canada | CA$762.36 Million |
|
Synergie SE
PA:SDG
|
France | €817.63 Million |
|
Angel Studios, Inc.
NYSE:ANGX
|
USA | $264.39 Million |
|
Nanjing Port Co Ltd
SHE:002040
|
China | CN¥1.35 Billion |
|
BELL AGROMACHINA ORD T (BSE)
NSE:BALUFORGE
|
India | Rs2.75 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Sinotherapeutics Inc. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sinotherapeutics Inc. A balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinotherapeutics Inc. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinotherapeutics Inc. A (2020–2025)
The table below shows the annual total liabilities of Sinotherapeutics Inc. A from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥146.12 Million ≈ $21.38 Million |
-18.96% |
| 2024-12-31 | CN¥180.30 Million ≈ $26.38 Million |
+19.12% |
| 2023-12-31 | CN¥151.36 Million ≈ $22.15 Million |
-2.38% |
| 2022-12-31 | CN¥155.05 Million ≈ $22.69 Million |
-3.47% |
| 2021-12-31 | CN¥160.62 Million ≈ $23.50 Million |
-11.14% |
| 2020-12-31 | CN¥180.76 Million ≈ $26.45 Million |
-- |
About Sinotherapeutics Inc. A
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extende… Read more